Neuroendocrine tumors (NET) are a very heterogeneous group of neoplasms; in recent years we have seen an increase in their incidence (3.65 /100,000/year) (1). They can be associated with hereditary endocrine syndromes (MEN, Von Hippel Lindau); they can occur at any age and the incidence is slightly higher in men than women (2). The aetiology of the neuroendocrine tumors is unclear; in most cases, inflammation of the bile ducts may be the underlying cause and for this reason, the initial patient’s evaluation should be focused on the different aspects concerning the oncological one and the possible sequelae of the biliary obstructions that can evolve in biliary sepsis. All neuroendocrine tumors have malignant potential.

The most frequent sites of extrahepatic biliary NETs are the common hepatic duct and the distal common bile duct (19.2%), followed by the middle of the common bile duct (17.9%), the cystic duct (16.7%), and the proximal common bile duct (11.5%). We can divide them into: well-differentiated and poorly differentiated. Considering the clinical features, neuroendocrine tumors can be divided into functional and non-functional. As regards the staging, we distinguish localized, regional and metastatic tumors.

Tumors derived from the bile duct are difficult to diagnose preoperatively, mainly because of its low incidence and difficult diagnostic process. However since cholangiocarcinomas account for about 80% of all primary biliary tumors, it is important to think about other options despite their low frequency when a patient presents with abnormal characteristics.

The most sensitive immunohistochemical markers are expressing neuron-specific enolase, synaptophysin and chromogranin A.

Liver function tests, alkaline phosphatase and bilirubin are often high. Sometimes, an anemia can appear in the presence of a chronic disease or in patients with more advanced disease. It is known that the measurement of chromogranin A is useful for the preoperative diagnosis of neuroendocrine tumors. Chromogranin A is elevated in 90% of neuroendocrine tumors of the intestine, and the levels correlate with tumor burden and the possibility of recurrence and, therefore, chromogranin A can be an effective biological marker for preoperative diagnosis of neuroendocrine tumors. Bile endocrine tumors remain silent until metastatizing or growing into neighboring organs, because of its uncommon diagnosis in early stages due to its low incidence, absence of serum markers and lack of symptoms related to the hormonal pattern.

Preoperative diagnosis of common bile duct carcinoma is extremely difficult, because it is foreshadowed by non-specific symptoms that include pain or discomfort in the right upper quadrant and weight loss. A 51-year-old woman presented a jaundice and severe bile duct dilatation. The enhanced CT scan showed a mass, approximately 15 mm in diameter, in the distal common biliary duct. The MRI and ERCP confirmed the mass. Chromogranin A value was negative. The diagnosis of well differentiated endocrine tumor of the biliary tract was done after its surgical resection was performed. The postoperative period was uneventful.

Extrahepatic biliary NETs are rare, and extrahepatic bile ducts reportedly account for only 0.32% of primary NET sites.

The prognosis for NET of the bile duct appears to be poor.
that can evolve in biliary sepsis. All neuroendocrine tumors have malignant potential.

The most frequent sites of extrahepatic biliary NETs are the common hepatic duct and the distal common bile duct (19.2%), followed by the middle of the common bile duct (17.9%), the cystic duct (16.7%), and the proximal common bile duct (11.5%). We can distinguish them into: well-differentiated, poorly differentiated. Considering the clinical features, neuroendocrine tumors can be divided into functional and non-functional. As regards the staging, we distinguish localized, regional and metastatic tumors.

Tumors derived from the bile duct are difficult to diagnose preoperatively, mainly because of its low incidence and difficult diagnostic process. However since cholangiocarcinomas account for about 80% of all primary biliary tumors, it is important to think about other options despite their low frequency when a patient presents with abnormal characteristics (3).

The most sensitive immunohistochemical markers are expressing neuron-specific enolase, synaptophysin and chromogranin A.

Liver function tests, alkaline phosphatase and bilirubin are often altered. Sometimes an anemia can appear in the presence of a chronic disease or in patients with more advanced disease. It is known that the measurement of chromogranin A is useful for the preoperative diagnosis of neuroendocrine tumors. Chromogranin A is elevated in 90% of neuroendocrine tumors of the intestine, and the levels correlate with tumor burden and the possibility of recurrence and, therefore, chromogranin A can be an effective biological marker for preoperative diagnosis of neuroendocrine tumors. Bile endocrine tumors remain silent until metastasize or invade neighboring organs, because of its uncommon diagnosis in early stages due to its low incidence, absence of serum markers and lack of symptoms related to the hormonal pattern (4).

Preoperative diagnosis of common bile duct carcinoma is extremely difficult, because it is foretold by non-specific symptoms that include pain or discomfort in the right upper quadrant level and weight loss.

Extrahepatic biliary NETs are rare, and extrahepatic bile ducts reportedly account for only 0.32% of primary NET sites.

The prognosis for NET of the bile duct appears to be poor (5).

Case report

A 51-year-old woman was found to have a marked dilatation of the intrahepatic bile duct during an ultrasonography performed, as part of a medical examination, and was admitted to hospital for further investigation (Figure 1). The patient showed: jaundiced skin, itching all over the body, issuance of dark urine and feces hypochoic; the laboratory tests it was found increase of direct bilirubin values, GGT and alkaline phosphatase.

An abdominal ultrasonography examination, together with a contrast-enhanced abdominal computed tomography scan, showed a mild dilation of the biliary tree and a solid hypochoic mass, approximately 15 mm in
Neuroendocrine tumor of the common bile duct: case report

diameter, in the distal common bile duct (Figure 2).

The common bile duct, in his proximal segment, presents a distinctly hyperdense tissue in the arterial phase occupying entirely the lumen for a 1.5 cm longitudinal extension and 1.2 cm transverse. Respect to the possibility of a classic common bile duct carcinoma, it showed an atypical post contrastographic behaviour, placing the suspect for a neuroendocrine tumor of the same (0.2 % of the common bile duct tumors).

MRI showed dilatation of the intrahepatic bile ducts, more evident in the left sections, with a maximum caliber at the left hepatic duct (9 mm). Dilation of the common bile duct (DT Max 11 mm) presenting empty signal, not univocal interpretation (Figure 3).

ERCP showed a lesion protruding into the lumen, at the level of the common hepatic duct, about 0.3 cm, irregularly oval, approximately 12 x 8 mm. The intrahepatic biliary ducts were moderately dilated and the gallbladder was not displayed. An endoscopic Papillotomy (PTe) and brushing of the lesion was made.
and it was positioned a 7 Fr nose-biliary drainage into the distal end of the right hepatic duct (Figure 4).

Furthermore, it was found a negative result to the pre-operative dosage of chromogranin A.

Based on these findings, a diagnosis of the distal common bile duct tumor was made, and the patient underwent a bile duct resection with the additional dissection of lymph nodes along the common bile duct, hepatic artery, and portal vein. The postoperative course was regular, the postoperative ileus resolved in 3rd postoperative day, no complications were observed during the course and the patient was discharged in the 10th postoperative day.

Histologic examination showed a well differentiated neuroendocrine tumor of the common hepatic duct (G1); with a maximum diameter of 1.8 cm, infiltrating the muscle layer; mitotic count index (10 HPF) <2; proliferative fraction (Ki67) ≤ 2% (IIC: CK7; CK20; CEA; chromogranin; synaptophysin; NSE, ki67; p53; EMA; S100; CD56; CK8-18).

The patient made an uneventful recovery even three weeks after the discharge.

Discussion and conclusion

The patient had a negative pre-operative result of chromogranin A and only after the histological examination a diagnosis of NET of common hepatic duct was made; in fact in this case a correct pre-operative diagnosis was more difficult, so it must be considered very rare.

Generally, the NET are diagnosed in the metastatic phase; their capability to metastasize is dependent on the site of occurrence of the primary tumor and the histological type. In particular, the most common site of metastasis is the liver (40-93%) followed by bone (12-20%) and lung (10.8%). It is estimated that approximately in 40% of patients with NET are present hepatic metastases at diagnosis.

NETs represent a very heterogeneous group of diseases, and for this reason it is not possible to define a unique treatment strategy. Also, being a quite rare tumor, it is imperative to consult a highly specialized center in which you can define a personalized therapy with a multidisciplinary medical approach. Among the different possible therapeutic options, surgery is the most used in potentially curative purpose: if the tumor is removed entirely, the surgery is on the whole the main step of the treatment and allows in many cases to cure it completely (6). For some neuroendocrine tumors it is possible to use local-regional therapies such as chemoembolization and the alcoholization (for metastases located in the liver areas difficult to reach by surgery) or cryosurgery and the high-frequency thermal ablation. The traditional radiotherapy is little used for the real cure of the tumor, but it is possible to use it with the aim of reducing the symptoms in more advanced stages. The adjuvant treatment should take into consideration the implications of the neuroendocrine system, especially the hypothalamic-pituitary-adrenal axis. In this perspective, the treatment with immunomodulators should be proposed in the future, similarly to other neoplastic as well as non-neoplastic diseases (7, 8). Targeted radiotherapy is based on the ability of some neuroendocrine tumors
Neuroendocrine tumor of the common bile duct: case report

References

8. Cappello M, Bravata I, Cocomulo G, Cacchiarelli M, Florea AM. Splenic liotellar cell hemangioendothelioma in patient with Crohn’s disease previously treated with immunomodulators and anti-TNF agents: a rare tumor linked to deep immuno-

